A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

Trial Profile

A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs FAZ 053 (Primary) ; PDR 001 (Primary)
  • Indications Breast cancer; Endometrial cancer; Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 30 Jun 2017 Planned End Date changed from 5 Oct 2019 to 6 Oct 2019.
    • 30 Jun 2017 Planned primary completion date changed from 5 Oct 2019 to 6 Oct 2019.
    • 16 Nov 2016 Planned End Date changed from 1 Feb 2019 to 1 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top